No changes in the percentages of CD3+ cells (pan-T cells) and CD19+ cells (pan-B cells) were detected, but the absolute quantity of CD3+ T cells was significantly decreased (= 0
No changes in the percentages of CD3+ cells (pan-T cells) and CD19+ cells (pan-B cells) were detected, but the absolute quantity of CD3+ T cells was significantly decreased (= 0.003) mainly due to the reduced abundance of CD8+ T cells (Physique S2). Open in a separate window Figure 2 Immune phenotype in peripheral blood of HT patients, by treatment group. further defined by the co-expression of CD25high and CD127low/?. Image_1.TIF (644K) GUID:?5426FD75-7ED5-4B7D-B665-9C1934CA987F Physique S2: Immune phenotype in peripheral blood of HT patients by treatment group. The complete number (cells/l) of the immune cell subsets was decided in 50 l of peripheral blood obtained from HT patients at >1 12 months post-transplant who were receiving therapy with MMF (MMF group, = 20) or who converted to EVL early (EVL-E, = 12) or late Fadrozole hydrochloride (EVL-L, = 8). Each circle represents one HT individual, and the mean and standard deviation are depicted as black bars. Significant differences between groups were determined by the MannCWhitney < 0.05. Image_2.TIF (215K) GUID:?FC8A0DF7-7722-467E-A302-C3CD5F6AA1A7 Figure S3: Effect of EVL, FK506, and MMF on CD4+ and CD8+ T cell proliferation. (A) CD4+ and CD8+ T cells isolated from six healthy donors were stained with CFSE and activated with anti-CD3/CD28 antibodies in the presence of different amounts of EVL (1 and 10 M), FK506 (100 nM and 1 M) and MMF (100 nM and 1 M) for5 days. Proliferation was quantified by gating CFSE-negative cells on CD4+ or CD8+ T lymphocytes. Results were normalized with respect to activated T cells and are shown as the mean and standard deviation of the six donors. Significant differences between CD4+ and CD8+ T cells were determined by Student's = 56) at short and long terms (prospective and retrospective cohorts), taking into account the time of EVL initiation: early (3 months post-transplant, EVL-E group) or late (>1 12 months post-transplant, EVL-L group) compared with mycophenolate mofetil treatment (MMF group). We show that early EVL conversion from MMF allows the increase of cytotoxic (CD56dim CD16+) NK and effector-memory (EM, CD45RA? CCR7?) CD8+ T cell subsets, which show a significantly higher level of expression of cytotoxic molecules, IFN- production and degranulation ability under activation. NK cell growth is accompanied by an altered balance of receptor expression, increasing the activation state, and lytic activity of those cells. Those changes are detected after Rabbit Polyclonal to EGR2 as little as 1 month after EVL conversion in association with the growth of regulatory T cells and the decrease in B cell frequency. However, no changes in the immune cells subsets were observed after late EVL initiation (EVL-L) compared with the MMF group. Our results imply that only early EVL conversion induces key changes in the post-transplant immune response, preserving an efficient anti-viral response, but simultaneously showing a limited ability to counteract the cytotoxic response to the allograft. HT patients could be candidates for EVL initiation, except those with baseline proteinuria or uncontrolled severe hyperlipidemia (9). A recent study showed that EVL initiation 4C6 weeks after HT with reduced-dose CsA led to better anti-rejection efficacy and a better security profile, although CMV contamination is more common than EVL initiation (10). However, there is contradictory evidence about this, which leaves many questions unanswered, and explains why no obvious strategy has yet emerged (11). In fact, data from your ISHL registry show that only about 13% of HT patients receive mTOR inhibitors as part of Fadrozole hydrochloride their long-term immunosuppressive maintenance regimen, including those receiving it as salvage therapy due to the development of CAV or renal insufficiency (12). It is widely accepted that this mTOR signaling pathway is crucial for the modulation of the innate and adaptive immune systems (13C15). mTOR is usually a ubiquitously expressed serine/threonine-protein kinase whose downstream signaling regulates diverse processes such as cell metabolism, proliferation, migration, protein translation, and survival in response to numerous environmental stimuli (e.g., availability of nutrients, growth factors, cytokines, and antigen-receptor signaling). Activation of the mTOR pathway is essential for maturation, development and cytokine production by dendritic cells (16C18). In T lymphocytes, mTOR directs the polarization of CD4+ T cells toward Th1, Th2, Th17, and regulatory T cells (Tregs) (19). In fact, mTOR-deficient CD4+ T cells fail to differentiate into helper T cells even in the presence of cytokines (20). Moreover, the growth and migration of CD8+ T cells into inflammatory tissues, and their differentiation into effector and memory CD8+ T cells are also regulated by mTOR (21C24). One of the best-analyzed effects of mTOR inhibitors Fadrozole hydrochloride around the immune system is the growth of Tregs arising from the immunosuppressive ability of these cells (25, 26). In response to IL-2, the level of activation of.